Carbon monoxide in acute lung injury

Area of Science:

• Critical care medicine
• Pulmonary medicine
• Gaseous therapeutics

Background:

• Acute lung injury (ALI) presents significant morbidity and mortality challenges in critical care.
• Current treatments for ALI are insufficient, necessitating novel therapeutic strategies.
• Endogenous carbon monoxide (CO), produced by heme oxygenase, exhibits protective qualities.

Purpose of the Study:

• To review the therapeutic potential of inhaled carbon monoxide (CO) in mitigating acute lung injury (ALI).
• To explore the protective mechanisms and signaling pathways involved in CO-mediated lung protection.
• To discuss the translation of laboratory findings to human clinical applications.

Main Methods:

• Review of in vivo and in vitro studies investigating inhaled CO effects on ALI models.
• Analysis of various ALI etiologies including ischemia-reperfusion, transplantation, sepsis, hyperoxia, and ventilator-induced lung injury (VILI).
• Examination of molecular mechanisms and signaling pathways modulated by CO exposure.

Main Results:

• Low-dose inhaled CO demonstrates anti-inflammatory, anti-apoptotic, and anti-proliferative effects in lung injury models.
• CO exerts protective effects against ALI induced by diverse stressors.
• CO modulates multiple signaling pathways, including MAPK, NF-κB, Akt, and apoptosis-related molecules.

Conclusions:

• Inhaled carbon monoxide is a promising therapeutic candidate for acute lung injury.
• CO's protective mechanisms involve complex molecular signaling pathways.
• Clinical trials are ongoing to evaluate the efficacy and safety of CO for human ALI treatment.